BUDGET IMPACT OF NIRAPARIB AS MAINTENANCE TREATMENT FOR MEDICARE PATIENTS WITH RECURRENT OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER WHO ARE IN COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY

被引：0
|
作者：
Neeser, K. [1 ]
O'Neil, W. M. [1 ]
Stern, L. [1 ]
机构：
[1] Analyt Laser, New York, NY USA
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.04.129
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN51
引用
收藏
页码：S21 / S21
页数：1
相关论文
共 50 条
  • [11] Efficacy and safety of niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer with complete or partial response to the last platinum-based chemotherapy: a subgroup analysis of the phase III NORA trial
    Yang, Jiaxin
    Wu, Xiaohua
    Zhu, Jianqing
    Song, Liang
    Feng, Yanling
    Wang, Jing
    Wu, Lingying
    Liu, Ziling
    Gao, Yunong
    Wang, Danbo
    Lou, Ge
    Yang, Hongying
    Zhou, Qi
    Kong, Beihua
    Huang, Yi
    Chen, Lipai
    Li, Guiling
    An, Ruifang
    Wang, Ke
    Zhang, Yu
    Yan, Xiaojian
    Lu, Xin
    Wang, Li
    Tan, Tao
    Dong, Juan
    GYNECOLOGIC ONCOLOGY, 2021, 162 : S18 - S18
  • [12] Niraparib in the treatment of previously treated advanced ovarian, fallopian tube or primary peritoneal cancer
    Rimel, B. J.
    Dockery, Lauren
    Randall, Leslie M.
    Moore, Kathleen
    FUTURE ONCOLOGY, 2020, 16 (33) : 2701 - 2711
  • [13] A feasibility study of low-dose, prolonged oral topotecan in patients with advanced ovarian, fallopian tube, or primary peritoneal serous cancer who have attained a complete clinical response following platinum-based chemotherapy
    Comander, A. H.
    Cannistra, S. A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2008, 18 (01) : 51 - 58
  • [14] Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study
    Abe, Marina
    Shoji, Tadahiro
    Chiba, Yohei
    Takatori, Eriko
    Kaido, Yoshitaka
    Nagasawa, Takayuki
    Kagabu, Masahiro
    Takahashi, Fumiaki
    Aida, Takeshi
    Baba, Tsukasa
    ANTICANCER RESEARCH, 2023, 43 (03) : 1265 - 1272
  • [15] Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US
    Wu, Lei
    Zhong, Lixian
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (02) : 187 - 195
  • [16] BUDGET IMPACT ANALYSIS OF NIRAPARIB AND OLAPARUB AS MAINTENANCE THERAPY FOR PLATINUM SENSITIVE, RECURRENT OVARIAN CANCER IN THE US
    Wu, L.
    Zhong, L.
    VALUE IN HEALTH, 2018, 21 : S22 - S22
  • [17] Outcomes based on treatment regimen in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer receiving intravenous or intraperitoneal platinum-based chemotherapy in combination with veliparib and bevacizumab
    Washington, C. R.
    Miller, A.
    Moore, K. N.
    Bell-McGuinn, K. M.
    Schilder, R.
    Walker, J. L.
    Brady, W. E.
    O'Cearbhaill, R. E.
    Guntupalli, S. R.
    Armstrong, D. K.
    Hagemann, A. R.
    Gray, H. J.
    Duska, L. R.
    Mathews, C. A.
    Chen, A.
    O'Malley, D. M.
    Gordon, S. W.
    Aghajanian, C.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 16 - 16
  • [18] Efficacy of niraparib on progression-free survival (PFS) in patients (pts) with recurrent ovarian cancer (OC) with partial response (PR) to the last platinum-based chemotherapy
    Mirza, Mansoor Raza
    Monk, Bradley J.
    Gil-Martin, Marta
    Gilbert, Lucy
    Canzler, Ulrich
    Follana, Philippe
    Waters, Justin S.
    Kridelka, Frederic
    Levy, Tally
    Benigno, Benedict B.
    Woie, Kathrine
    Provencher, Diane M.
    Lueck, Hans-Joachim
    Herraez, Antonio Casado
    Lesoin, Anne
    Buscema, Joseph
    Hellman, Kristina
    Rimel, B. J.
    Hazard, Sebastien
    Matulonis, Ursula A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [19] Effect of prior olaparib maintenance therapy for platinum sensitive recurrent ovarian cancer on response to subsequent platinum-based chemotherapy
    Nakazawa, Hiroshi
    Nagao, Shoji
    Narita, Moyu
    Shibutani, Takashi
    Jimi, Tomoatsu
    Yano, Hiroko
    Kitai, Miho
    Shiozaki, Takaya
    Yamaguchi, Satoshi
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2022, 48 (05) : 1248 - 1254
  • [20] What Is the Benefit of Bevacizumab Combined with Chemotherapy in Patients with Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Malignancies?
    Cheng, X.
    Moroney, J. W.
    Levenback, C. F.
    Fu, S.
    Jaishuen, A.
    Kavanagh, J. J.
    JOURNAL OF CHEMOTHERAPY, 2009, 21 (05) : 566 - 572
12345